Tem­pest Ther­a­peu­tics jumps on­to Nas­daq in merg­er with strug­gling Mil­len­do Ther­a­peu­tics; Bio­haven hits $100M mile­stone as it gears up for a late-stage study in mi­graine pa­tients

Less than a month af­ter land­ing a Big Phar­ma part­ner on one of its lead on­col­o­gy pro­grams, Tem­pest Ther­a­peu­tics is back­flip­ping on­to Nas­daq through a re­verse merg­er with Mil­len­do Ther­a­peu­tics.

Back in Jan­u­ary, Mil­len­do shut down the sole re­main­ing ear­ly-stage study for its NK3R an­tag­o­nist MLE-301 — just nine months af­ter pulling the plug on a piv­otal study for its lead drug liv­o­le­tide. The biotech planned some deep cuts for the re­main­ing staff, while look­ing for a sale or merg­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER